Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2024 01:00 ET | Source: BioVersys

BioVersys Joins EU-Funded RespiriNTM Programme to Accelerate Development of Its Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases

BASEL, Switzerland, Oct. 22, 2024 (GLOBE NEWSWIRE) -- RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive fundingBioVersys taps into key expertise of the...
October 16, 2024 01:00 ET | Source: BioVersys

Bioversys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business Update

BV100 Phase 2 preliminary results suggest BV100 is generally safe and well tolerated and showed strong initial signs of efficacy in VABP patientsStrategic investment from GIBF and launch of...
September 24, 2024 01:00 ET | Source: BioVersys

Nature Reviews Highlights Significant Successes of Antibiotic Collaboration and Calls for Sustainable R&D Funding Schemes

BASEL, Switzerland, Sept. 24, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for...
September 11, 2024 01:00 ET | Source: BioVersys

Bioversys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China

BASEL, Switzerland, Sept. 11, 2024 (GLOBE NEWSWIRE) -- GIBF2 to invest US$ 6m in BioVersys BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3...
June 04, 2024 01:00 ET | Source: BioVersys

BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- CF AMR Syndicate awarded BioVersys up to £ 500,000 to support project addressing resistant non-tubercular mycobacteria (NTM) lung infections...
May 07, 2024 01:00 ET | Source: BioVersys

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C...